Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00336856 · ClinicalTrials.gov registry record · Phase 2
Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
A Phase 2 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00336856 is a Phase 2 study that has completed, run by University of Pittsburgh. The registered enrollment target is 35 participants.
The verdict
NCT00336856, a Phase 2 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
Research Hypothesis: Subjects in the study population who are treated with cetuximab in combination with irinotecan will have higher response rates than subjects treated with irinotecan alone.
Interventions
- DRUG Cetuximab
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2006-06 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00336856
The ClinicalTrials.gov registry entry for NCT00336856 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cetuximab is the first listed.
NCT00336856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00336856 about?
NCT00336856 is a clinical study titled "Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy". Research Hypothesis: Subjects in the study population who are treated with cetuximab in combination with irinotecan will have higher response rates than subjects treated with irinotecan alone.
What is the current status of trial NCT00336856?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2006-06. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00336856?
The interventions under investigation include: Cetuximab (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00336856?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.